Adocia
- Company typePublic
- Founded2005
- HeadquartersLyon, France
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Adocia firmographics
Firmographics- Name
- Adocia
- Legal name
- ADOCIA
- Website
- https://adocia.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Adocia industry classification
Industry- Product category
- Diabetes & Obesity Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Insulin & Analog Biosimilars (HLAAAHAD)
- akta.pro secondary industry
- Insulin & Analog Biosimilars (HLAIAFAB)
Keywords
Where Adocia is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Adocia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing and Milestone Payments: Adocia generates revenue through licensing agreements with pharmaceutical partners. The company receives upfront payments, milestone payments tied to clinical and regulatory achievements, and double-digit royalties on net sales. A $20 million milestone payment is tied to marketing authorization in China for BioChaperone Lispro.
- Fundraising: Adocia raises capital through private placements and public offerings to fund R&D operations. The company completed a €10 million fundraising in December 2025 and a €9.7 million private placement in February 2025.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Adocia product offering
Product offeringCore offering
Adocia develops innovative formulations of already-approved therapeutic peptides and proteins, principally insulins and metabolic hormones, for the treatment of type 1 and type 2 diabetes and obesity. The company leverages its proprietary BioChaperone formulation platform and AdoShell immunoprotective scaffold technology, out-licensing clinical-stage drug candidates to pharmaceutical partners after proof-of-concept in humans in exchange for upfront payments, milestone payments, and royalties on net sales.
Product overview
Adocia is a clinical-stage biotechnology company offering a portfolio of innovative diabetes and obesity treatments built on its proprietary BioChaperone technology platform. The product portfolio includes: BioChaperone Lispro (THDB0206), an ultra-rapid insulin formulation; BioChaperone Combo, a co-formulation of lispro and glargine; ADO09, a co-formulation of pramlintide and insulin A21G; and AdoShell Islets, an immunoprotective cell therapy scaffold. These products range from innovative formulations of already-approved peptides and proteins to specialized delivery technologies.
Differentiator
Problem solved
Functional benefit
Brands
- BioChaperone®: Proprietary technology platform for innovative insulin formulations
- AdoShell®
Products and services
- BioChaperone Lispro (THDB0206) Ultra-rapid insulin formulation combining Adocia's proprietary BioChaperone technology with insulin lispro. Demonstrated non-inferior HbA1c reduction compared to Eli Lilly's Humalog in Phase 3 trials for both type 1 and type 2 diabetes patients, and out-licensed to Tonghua Dongbao for China and Asian markets.
- BioChaperone Combo
Quantifiable outcome
- Non-inferior HbA1c reduction compared to Eli Lilly's Humalog in Phase 3 trials
- +3 more outcomes
Companies that use Adocia
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
Adocia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Adocia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Tonghua DongbaocoreLicensing agreement signed in 2018 for BioChaperone Lispro (THDB0206) in China and Asian markets. Includes $20 million milestone payment upon marketing authorization in China plus double-digit royalties on net sales. Partner completed Phase 3 trials with positive results in both type 1 and type 2 diabetes patients.
- Eli LillycoreMajor historical partnership representing over $150 million in revenue. The partnership involved insulin formulation technologies developed by Adocia.
- OVHminorWeb hosting provider for Adocia's corporate website.
Scale indicators9 records
Recent moves7 records
Expansion highlights5 records
Adocia competitors and assessment
Company assessmentDirect peers
- MannKind Corporation: Clinical-stage and commercial biotech focused on endocrine diseases, including inhaled insulin (Afrezza) and GLP-1/glucagon programs. Highly comparable to Adocia in developing reformulated/innovative insulin and metabolic hormone therapeutics.
- Zealand Pharma: Danish peptide therapeutics company developing novel GLP-1, amylin, and other metabolic peptides for diabetes and obesity. Direct peer given shared focus on innovative peptide/protein formulations for metabolic diseases.
- vTv Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for type 1 diabetes (T1D) and other metabolic diseases. Comparable in being a small-cap clinical-stage company tackling diabetes with innovative mechanisms.
Emerging players
- Biolaxy (Tonghua Dongbao-related biosimilars): Tonghua Dongbao is one of China's largest insulin manufacturers and Adocia's licensing partner for BioChaperone Lispro. A key regional peer given its commercial insulin franchise in China and direct involvement in the THDB0206 program.
- Vertex Pharmaceuticals: Has a leading cell-therapy program (VX-880/zimislecel) for type 1 diabetes. Highly comparable to Adocia's AdoShell Islets program as a competitor/peer in pursuit of a functional cell-based cure for T1D.
- Sigilon Therapeutics: Developer of cell-encapsulation therapies for type 1 diabetes and other diseases. Directly comparable to Adocia's AdoShell immunoprotective scaffold approach to enable cell therapy without chronic immunosuppression.
- Provention Bio (sanofi): Now a Sanofi subsidiary focused on autoimmune and inflammatory diseases including type 1 diabetes (Tzield). Comparable emerging diabetes biotech that achieved a strategic exit via acquisition.
Broad incumbents
- Sanofi (Diabetes/General Medicines): Global pharmaceutical incumbent with a major insulin franchise (Lantus, Apidra, Toujeo) and broad metabolic disease portfolio. Represents the type of large pharma partner or competitor Adocia engages with for licensing and competes against commercially.
- Novo Nordisk: World's largest insulin producer (NovoLog, Fiasp, Levemir, Tresiba) and dominant GLP-1 player (Ozempic, Wegovy). Adocia's CFO/COO came from Novo Nordisk, and Novo represents both a benchmark competitor and a potential strategic acquirer/partner.
- Eli Lilly: Maker of Humalog and Lyumjev (the comparator in Adocia's Phase 3 trials) and major diabetes/obesity player. Historical Adocia partner (>$150M in past revenue) and a key reference point for any future Western-market licensing deal.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Adocia social profiles
Digital presenceAdocia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adocia leadership team
Management profileNumber of profiles
Profiles9 records
Adocia funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adocia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adocia
What does Adocia do?
Adocia develops innovative formulations of already-approved therapeutic peptides and proteins, principally insulins and metabolic hormones, for the treatment of type 1 and type 2 diabetes and obesity. The company leverages its proprietary BioChaperone formulation platform and AdoShell immunoprotective scaffold technology, out-licensing clinical-stage drug candidates to pharmaceutical partners after proof-of-concept in humans in exchange for upfront payments, milestone payments, and royalties on net sales.
Is Adocia a public or private company?
Adocia is a public company. It is classified as public and is currently operating.
When was Adocia founded?
Adocia was founded in 2005. It employs 51 to 100 people.
Where is Adocia based?
Adocia is headquartered in Lyon, France, in the Europe region.
How does Adocia make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are fundraising.
Who are Adocia's main competitors?
Direct peers on record are MannKind Corporation, Zealand Pharma and vTv Therapeutics. Emerging players are Biolaxy (Tonghua Dongbao-related biosimilars), Vertex Pharmaceuticals, Sigilon Therapeutics and Provention Bio (sanofi). Broad incumbents are Sanofi (Diabetes/General Medicines), Novo Nordisk and Eli Lilly.
Does Adocia have an API?
No public API is recorded for Adocia.
What industry is Adocia in?
Adocia's product category is Diabetes & Obesity Biopharmaceuticals. Its primary akta.pro industry code is HLAAAHAD, Insulin & Analog Biosimilars, with a secondary code of HLAIAFAB, Insulin & Analog Biosimilars. Its NAICS code is 3254 and its SIC code is 2834.